Treatment Information

Back

Breast Cancer treatment details. Chemotherapy.

Churchill Hospital, Oxford, United Kingdom.

Survival: monthsCountry:United Kingdom
Toxiciy Grade:4City/State/Province:Oxford
Treatments:ChemotherapyHospital:Churchill Hospital
Drugs:Journal:Link
Date:May 2002

Description:

Patients: This Phase II study involved 44 women with advanced and/or metastatic breast cancer. Most patients had been treated previously with other regimens. Patients were divided into two groups – 22 in Group A and 20 in Group B. (Two patients were part of a third group that was discontinued.)

Treatment: Patients in group A were administered the oral drug capecitabine (xeloda). Patients in group B were treated with the drug paclitaxel (intravenous).

Toxicity: In group A, there was grade 3-4 neutropenia. Other toxicities included: nausea, diarrhea, vomiting, fatigue, stomatitis, pyrexia, and hand-foot syndrome.

Results: Median survival was 7.6 months for patients in group A.

Support: This study was sponsored by F. Hoffmann-La Roche. Roche markets xeloda.

Correspondence: D. Talbot, MD




Back